Advanced Filters
noise

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 793 clinical trials
H Hanna Chainay

Lack of Decision-making in Patients With Alzheimer's Disease : Functions Involved and the Daily Consequences

Early in its development, Alzheimer's disease causes not only brain damage affecting different regions of the brain, such as the entorhinal cortex, the anterior cingulate cortex, and the prefrontal lobe, but also a cognitive deficit affecting several functions, such as episodic memory, executive functions, or working memory. Although these different …

60 years of age All Phase N/A
P Patrik Johansson, MD, MPH

Indian Transforming Alzheimer's Care Training (INTACT)

INTACT will utilize a group-randomized trial, to test the effectiveness of a culturally informed provider training and "dementia friendly clinic" intervention for detection and appropriate management of AI/AN patients with ADRD and MCI in 28 urban and rural clinics serving AI/ANs.

18 years of age All Phase N/A

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

50 - 89 years of age All Phase 2
C CRISTIAN RIPOLI

Next-Generation alzheImer'S Therapeutics

Is this the right time to use next-generation approaches in Alzheimer's disease (AD)? In recent years, several large clinical trials testing treatments for AD have failed, putting the entire field on a reset. AD drug trials have almost exclusively sought to use antibodies targeted toward misfolded amyloid and tau proteins. …

18 - 80 years of age All Phase N/A
I In-Jin Jang, Doctor

A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People

The study is a Phase I, randomized double-blind, placebo-controlled, single and multiple dosing, dose-escalation study of the oral administration of DDN-A-0101 in healthy adults and elderly subjects

19 - 75 years of age All Phase 1
A Anne Mortensen

Dementia Care Partner Hospital Assessment Tool

The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. …

18 years of age All Phase N/A
A Alireza Faridar

Systemic and Central Inflammation in AD

Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given …

50 - 86 years of age All Phase 2
N Nadine BEN MESSAOUD, MA

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

This study aims to analyse, in vivo, the interplay between microglial activation and tau pathology in Alzheimer's disease (AD) using [18F]-DPA-714 and [18F]-Ro948 tracers by Position Emission Tomography (PET), and their consequences on synaptic density using [11C]-UCB-J, a recent PET radioligand. By coupling advanced neuroimaging techniques in AD patients, while …

18 years of age All Phase N/A
C Chloe Meehan, BS, MA

DORA and LP in Alzheimer's Disease Biomarkers

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the fluid around the brain known as cerebrospinal fluid (CSF). Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

65 years of age All Phase 2

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.

50 - 85 years of age All Phase 2

Simplify language using AI